NewLimit

NewLimit is a longevity biotech company that has achieved several key milestones much faster than its founders expected. Its AI platform, Ambrosia, enables it to rapidly predict and iterate on novel transcription factor combinations that target specific cell types to reduce age while preserving cell identity. The company is targeting a therapeutic opportunity that one of its founders claims is 100 times larger than any prior biotech product, backed up by the fact that aging is upstream of a multitude of diseases. Still, at its current stage, NewLimit has a long path ahead to bring a single disease-targeting drug to market and an even longer path to achieve its goal of developing general-purpose medicines for the broader population.